onc brain

Retrospective real-world analysis of commercial and Medicare claims databases, indexed at the date ADT was prescribed. Data cutoff May 2024. Presented at ASCO GU 2026 and discussed in a UroToday interview, not a full paper.

~17,000 pts with prostate cancer receiving ADT. ~90% GnRH agonist, ~10% GnRH antagonist (degarelix ~two-thirds, relugolix ~a third). Agonist pts were older, more likely on Medicare, and had longer median f/u.

Primary: two- and three-point MACE. Secondary: MACE before vs after 2021, the year HERO and PRONOUNCE reported.

Overall MACE ~four per 100 person-yrs. Antagonist pts had ~37% numerically lower MACE than agonist pts. Preexisting CVD carried ~11 per 100 person-yrs, about threefold. Post-2021 showed a modest reduction vs pre-2021.

Direction matches HERO, which the presenter cited for lower MACE with relugolix vs agonist. PRONOUNCE was cited for the value of cardiologist involvement, which frames the preexisting-CVD finding as a referral question, not only a drug-choice question.

Baseline age, payer and f/u imbalances bias the crude class comparison. MACE misses earlier cardiometabolic harm (diabetes, metabolic syndrome, renal dysfunction), as the interviewer pointed out. The pre/post-2021 shift is a secular trend with no causal link to the trials.

The more robust signal is the preexisting-CVD rate, which identifies who needs cardiovascular co-management whatever the ADT class. A PCF consensus statement on risk-tiered cardiology referral is described as forthcoming.

Retrospective claims comparison, 'numerically lower' with no CI or adjustment reported; agonist group older, more Medicare, longer f/u. Antagonist group mostly degarelix.

Prospective single-centre observational cohort following STROBE. Pts were resected between 1990 and 2001, follow-up closed Dec 2005, median f/u 43 mo. Cox models used forward selection, with a 200/415 learning-validation split for internal validation only.

615 assessable white pts with primary cutaneous SCC at any body site, median age 73, 5% immunosuppressed. Excluded: SCC in situ, keratoacanthoma, collision tumours, and recurrent SCC treated elsewhere.

No pt received adjuvant RT. Every resection reached tumour-free margins by 3D-histology, with re-excision as needed, so outcomes reflect surgery alone.

The source states the primary endpoints as time to metastasis and time to local recurrence, each measured from diagnosis of the primary. Seven candidate predictors were chosen a priori.

26 (4%) metastases and 20 (3%) local recurrences. No tumour ≤2.0 mm metastasized. The thinnest tumour that metastasized was 2.8 mm thick.

Clayman and colleagues reported LR in 12% (15 of 130) of primary SCC. Margin-controlled resection here gave 3% (20 of 615). The authors cite an Australian series of 266 pts with nodal disease that also supports tumour thickness over horizontal size.

Follow-up after the early period relied partly on mailed questionnaires to treating physicians. New field-cancerization SCC can mimic local recurrence. University referral may have enriched for poorly differentiated tumours.

Thickness, immunosuppression and desmoplasia outperformed Broders' grade and horizontal size as prognostic factors. The authors propose thickness-based T1-T3 cutoffs (≤2.0, 2.1-6.0, >6.0 mm) with "d" and "i" modifiers. The study does not test whether any treatment changes the high-risk course.

Single-centre prognostic cohort, model selected by forward selection with events per predictor below 5. Validated only internally; no external cohort.

Retrospective single-institution series of 671 lesions treated 1972-2007. Mean follow-up 38.016 mo (range 1-351). Actuarial cure rate by life-table method; chi-squared for dose and size associations.

Basal and squamous cell carcinomas of the skin overlying the nasal cartilages. Histology split of the full cohort not given in the source excerpt. Relapses included 10 lesions already recurrent after prior non-radiological treatment.

CRT in 668 lesions: 55-60 kV, HVD 2-12 mm, 5 Gy/fx twice weekly, total 30-75 Gy (median 55 Gy). Margin 0.5-1 cm, 1.5 cm for morpheaform BCC. Septal cartilage shielded with 1 mm Pb nostril inserts at the alae.

CR 98.80% at 1 mo; 5-yr cure 88.09%, 10-yr 86.51%. Recurrence 38 lesions (13 central, 25 marginal), onset 3-96 mo. No relationship between relapse and dose or size.

Cosmesis good or acceptable in 96.84%; 16 lesions not acceptable. Authors report no complications or sequelae, and flag the 7 newly not-acceptable cases for continued follow-up.

No contemporaneous comparator. The authors cite randomised facial BCC data comparing RT with surgery: cosmesis was similar on nasal skin but control favoured surgery, in tumors under 4 cm treated with mixed RT techniques. Mohs surgery, the usual comparator for nasal BCC today, is not addressed.

Toxicity is clinician-rated cosmesis without a named scale, and a mean follow-up near 3 years is short for late cartilage effects. The null dose-relapse finding is likely confounded by dose being chosen by lesion size.

The data support kV RT as an effective, cartilage-sparing option for nasal skin carcinoma, where tight adherence of skin to cartilage complicates excision. They do not establish superiority over surgery, and the marginal-failure pattern raises the question of whether margins were adequate.

Single-institution retrospective series, 1972-2007, no surgical comparator; the authors' claim of superiority over other modalities rests on cross-literature comparison this design cannot support.

Retrospective single-institution series, 114 pts and 134 lesions treated Nov 2006 to Dec 2011. Analysis per lesion; median follow-up 33 mo.

92 BCC and 42 SCC, all clinically N0. 77.3% definitive, 22.7% adjuvant after excision with positive or close margins.

Ir-192 HDR plesiotherapy, 3 Gy/fx, 3 fx/wk; mean 48.79 Gy (45-54) for BCC and 50.55 Gy (45-57) for SCC, prescribed 3-5 mm below the surface with a 0.5-1 cm margin. Leipzig 2 or 3 cm applicators for flat lesions ≤2 cm (75.4%); customized molds for raised or larger lesions.

Overall 3y/5y DFS 95.12%/93.36%, CR 98%. Recurrent lesions did worse than primary (85.9% vs 95.6% at 5y, p=0.003); applicator and definitive vs adjuvant did not separate DFS.

Acute RTOG G3 40.3%, G4 2.2%; toxicity higher with definitive intent (OR 2.928, p=0.013) and borderline with molds (p=0.067). Late G0-1 95.2%; cosmesis excellent/good 82%.

Authors place results alongside the Kohler Leipzig series (91% complete remission) and Guix's mold series (5y DFS 98%). They cite one randomized surgery vs RT trial as the only head-to-head data, with no numbers given in source.

Molds treated larger lesions, so mold vs Leipzig DFS and toxicity differences cannot be separated from size. Reported recurrence counts do not add up, and the acute toxicity figure differs between abstract and results.

Supports surface HDR as a definitive alternative to excision for small primary NMSC. It does not settle optimal fraction size, and the high acute G3 rate argues for weighing applicator and dose per fraction for larger lesions.

Retrospective single-institution series, no comparator arm; applicator comparison confounded by lesion size and location; DFS per lesion with 33-mo median f/u.